DVA

Business profile & competitive position

DaVita Inc. (DVA) operates in the Healthcare sector, specifically the Medical - Care Facilities industry, and is one of the largest U.S. providers of kidney dialysis services. As of December 31, 2025, it ran 2,657 outpatient dialysis centers in the United States serving roughly 200,500 patients. The company also maintains an international footprint of 585 outpatient dialysis centers across 14 countries, serving about 94,500 patients, along with integrated kidney-care and ancillary service lines.

The scale is meaningful: U.S. dialysis represented approximately 86% of consolidated revenues, and the filing notes that nearly all non-hospital dialysis profits came from commercial payors. That concentration tells you two things. First, DaVita has built a high-volume, network-driven business that benefits from patient retention and long-term treatment relationships. Second, its economics are not evenly distributed across payors; commercial insurance rates effectively subsidize the lower government reimbursement rates common in Medicare and Medicaid dialysis programs.

The financial-return evidence is more nuanced. The net margin is 6.0%, which is modest for a healthcare services leader and suggests that after all reimbursement, labor, and medical-supply costs, only a thin slice of revenue drops to the bottom line. Return on equity is -123.6%, a striking figure that does not imply an operating loss; it reflects a deeply negative book-equity base, likely driven by liabilities, share buybacks, or accumulated deficit dynamics. Because of that, ROE is not a clean read on competitive moat here, but the negative number does flag capital-structure risk. On the qualitative side, DaVita points to an 11-year streak as an industry leader in CMS’s Quality Incentive Program and a 10-year streak in the Five-Star Quality Rating System. Those quality metrics support the idea of an operational moat, even though the balance-sheet math distorts traditional return measures.

Financial posture

DaVita currently carries an $11.5 billion market cap and trades at a P/E of 15.4 based on a price of $178.92. At face value, a 15.4xmultiple sits near the middle of the range for mature healthcare-services companies—neither obviously cheap nor obviously expensive. The 6.0% net margin is the more telling figure: it shows that revenue must be earned at scale because per-dollar profitability is limited. A beta of 0.83 indicates the stock historically moves less than the broader market, which is consistent with a defensive, demand-stable healthcare business.

The negative ROE of -123.6% is the outlier. Rather than signaling losses, it usually means shareholders’ equity is negative while the firm still produces positive net income. That combination can occur when debt, operating leases, or accumulated treasury-stock activity push book equity below zero. For a capital-intensive dialysis model—centers, equipment, and long-term patient commitments—this is a balance-sheet profile that demands close attention, especially when combined with the commercial-payer profit concentration noted in the 10-K. From a technical snapshot, RSI is 44.8 and the 50-day EMA is $187.15, meaning the stock is trading below its near-term moving average.

Strategic priorities & outlook

DaVita’s most recent 10-K frames its near-term priorities around three operational goals. The first is to reimagine kidney care to be more preventative, better integrated, outcome-focused, lower-cost, and personalized at scale. The second is to build integrated care capabilities across the entire renal care continuum, from chronic kidney disease through end-stage kidney disease and into kidney transplantation. The third is to support the Comprehensive Kidney Care Contracting model, which aims to delay disease progression, promote home dialysis when clinically appropriate, and incentivize transplants.

These priorities align with how Medicare is increasingly paying for value rather than volume. If DaVita can shift more care upstream—keeping patients healthier longer and moving suitable patients to lower-cost home settings—it could protect margins in a reimbursement environment that generally pressures in-center dialysis rates. At the same time, the strategy depends on execution: care coordination, data integration, and patient adoption of home dialysis are all operational challenges, not straightforward cost cuts.

Macro & geopolitical exposure

As a Medical - Care Facilities operator, DaVita is exposed to a set of macro and policy risks that are inherent to the industry. The single largest factor is government reimbursement policy, especially Medicare and Medicaid dialysis rates administered through CMS. Any change to the End-Stage Renal Disease Prospective Payment System, the Quality Incentive Program, or the Five-Star Quality Rating System can move revenue and margin directly. Regulatory and legislative risk is therefore a permanent feature of the business model.

Commercial insurance rates are the second major factor. Because nearly all non-hospital dialysis profits come from commercial payors, changes in employer-sponsored insurance coverage, payer mix, or legislative caps on commercial dialysis reimbursement can alter profitability even if patient volumes are steady. Labor inflation also matters: dialysis centers require nurses, technicians, and specialized staff, so wage pressure in healthcare services shows up in operating costs. Supply-chain exposure includes dialyzers, dialysis machines, and pharmaceuticals such as erythropoiesis-stimulating agents; tariffs, manufacturing constraints, or transportation disruptions can affect both cost and availability. The international segment adds currency risk across 14 countries. Finally, demographic trends—aging populations and rising rates of diabetes and hypertension—support long-term demand, even as they also increase pressure on public budgets.

Recent developments

The recent news flow has been mixed, which fits a stock that has drawn both value-oriented and momentum-oriented attention. On October 2, 2026, Zacks published “DaVita HealthCare (DVA) Laps the Stock Market: Here's Why,” noting a period of outperformance. A few days earlier, on September 24, 2026, the same outlet ran “DaVita HealthCare (DVA) Registers a Bigger Fall Than the Market: Important Facts to Note,” highlighting a pullback. That kind of reversal in a single week underscores how quickly sentiment can shift.

On September 29, 2026, The Motley Fool carried the headline “This Warren Buffett Stock Is Up 58%. History Says This Is What Happens Next,” framing DaVita as a namesake holding with a substantial trailing gain. That same week, on September 21, 2026, MarketBeat included DaVita among “3 Surging Stocks That Don't Need the AI Boom to Keep Winning,” suggesting the stock is being viewed as a non-technology momentum candidate. Taken together, the headlines show a company being discussed both as a Berkshire-backed quality name and as a short-term trading vehicle, which can create gap-up or gap-down behavior around events.

Earnings behavior & post-earnings drift

DaVita has beaten earnings expectations in 6 of the last 8 reported quarters, a 75% beat rate, with an average earnings surprise of 2.3%. Across those eight quarters, the average 5-day price move after earnings was 6.36%, classified as an “up” drift. On the surface that suggests the market has rewarded DaVita beats. The underlying quarter-by-quarter data, however, tells a more complicated story.

Looking at the four most recent reports: on February 2, 2026, EPS of $3.40 beat the $3.24 estimate by 4.9% and the stock jumped 21.17% the next day and 23.79% over five days. On May 5, 2026, EPS of $2.87 crushed the $2.41 estimate by 19.1%, sending the stock up 23.46% the next session and 27.7% over five days. But on August 4, 2026, EPS of $4.02 beat the $3.88 estimate by 3.6%yet the stock crashed 17.24% the next day and 21.78% over the following five days. Before that, on October 29, 2025, EPS of $2.51 missed the $3.17 estimate by 20.8%, producing a 6.17% next-day drop and a 4.27% five-day decline.

The takeaway for post-earnings behavior is that a beat does not guarantee a continued directional drift. The August 2026 report is the cleanest example: the headline number was higher than the consensus estimate, but the stock price moved sharply lower, presumably because forward guidance, commercial payer mix, or another operational concern dominated the conversation. The +27.7% and +23.79% moves in the two prior quarters were large enough to push the average five-day drift positive, but that average masks a wide and unpredictable range. DaVita’s next scheduled report is November 4, 2026, after the close, with a consensus EPS estimate of $3.55.

For a deeper dive into how institutional analysts are interpreting DaVita’s valuation, balance sheet, and earnings setup heading into the November 4 report, review the full institutional verdict rather than relying on headline numbers alone.